Verastem Corp (VSTM): Long-Term Debt to Capital Ratio

Verastem, Inc. (VSTM) seeks dominance in ovarian cancer therapy by suppressing RAS/MAPK pathways using avutometinib, employing unique malignant cell survival blocking methods to capture vacant niches. This chart reflects an asset value of 1.50, while the business relies on FDA decisions, as the absence of sales makes the company dependent on regulatory verdicts.

This indicator measures the ratio of long-term liabilities to equity, allowing for an assessment of financial stability and bankruptcy risk during prolonged periods of unprofitability. An analysis of long-term debt to equity for Verastem, Inc. (VSTM) confirms management's ability to fund costly developments of targeted cancer drugs without critical debt dependence, ensuring the asset's reliability.